Board

PExA's board and management include individuals with extensive experience and knowledge. Their task is to identify our targets and our strategy.

  • Claes Holmberg

    Chairman

    Claes Holmberg, born in 1954, holds an MSc in Engineering Physics and a PhD in Theoretical Physics. Holmberg has been involved in the development of PExA’s business since 2012, two years before the company was incorporated. Holmberg is a Board member of GOKAP Holding AB and Torpa Industrier, and CEO of GOKAP Invest AB. He has previous experience as Deputy CEO of Nobel Pharma AB/Nobel Biocare AB, CEO of MediTeam AB/Biolin AB, Biolight AB and Emotra AB. Holmberg has also previously served as Chairman and Board member of several medical technology companies and national interdisciplinary research programmes.

  • Anna-Carin Olin

    Board member

    Anna-Carin Olin, born in 1960, is a researcher and the originator of PExA. Olin is a medical doctor, senior consultant and Professor of Occupational and Environmental Medicine. She leads the research on the PExA method at the Department of Occupational and Environmental Medicine at Sahlgrenska Academy, University of Gothenburg. Olin has been involved in the development of PExA’s business since the 2000s.

  • Björn Dahlöf

    Board member

    Björn Dahlöf, born in 1953, MD, PhD, FESC, FACC, is a licensed physician, Associate Professor and specialist in general internal medicine, with almost 40 years of experience from hospital-based clinical work. He has extensive research experience in cardiovascular medicine, with more than 400 scientific publications. Dahlöf has acted as an advisor to most major pharmaceutical companies within drug development and strategy and has co-founded several life science companies. He is currently CSO of Cereno Scientific, a company developing future therapies through epigenetic modulation for cardiovascular and pulmonary diseases, currently focused on pulmonary arterial hypertension and pulmonary hypertension associated with lung fibrosis.

  • Martin Malmström

    Board member

    Martin Malmström, born in 1975, is a business-oriented sales and marketing executive with a Master of Business Administration degree. He has extensive global experience from the pharmaceutical, medical technology and labtech industries, spanning more than 20 years. Martin has held senior positions in several prominent companies, including Sanofi and Mölnlycke Health Care. He is currently CCO of Biolin Scientific, with responsibility for sales, product management, marketing and service. He has served as an independent Board member of PExA since 2023.

Management

  • Tomas Gustafsson

    CEO

    Tomas Gustafsson, born in 1971, was educated in Mechanical Engineering at Chalmers University of Technology and at Chalmers School of Entrepreneurship in Gothenburg. Gustafsson has extensive experience in developing and commercialising medical technology products internationally. For 17 years, he served as CEO of the listed company Micropos Medical, which he co-founded together with four oncology professors and Chalmers Innovation. At Micropos, an initial idea was developed into several approved products that are now used to enable a dramatic change in prostate cancer treatment, reducing treatment from eight weeks of daily radiotherapy to, in some cases, a single treatment session.

  • Svante Höjer

    Manager Engineering and Design

    Svante Höjer, born in 1961, has been project manager for PExA since 2011, with responsibility for technical development. He is also responsible for the protection of the Company’s intellectual property rights and intangible assets. Höjer has previously served as technical lead at PExA. He holds an MSc in Engineering Physics and a PhD in Physics/Photonics.

  • Jörgen Östling

    Manager, Research and Biochemical Analysis

    Jörgen Östling, born in 1962, has been employed by PExA since 2018. Östling holds a PhD in Microbiology and has extensive experience in proteomics and bioinformatics. He has worked for more than 20 years in the pharmaceutical industry, where during the last six years he focused, among other things, on the identification of biomarkers for precision medicine in respiratory diseases such as asthma and COPD. Jörgen most recently came from AstraZeneca, where he was involved in the development of methods for biochemical analysis of PEx samples.

  • Åsa Wheelock

    Scientific Advisor, PhD, Associate Professor

    Åsa Wheelock, born in 1970, holds a PhD in Pharmacology and Toxicology from the University of California, Davis (2004), with doctoral research focused on the synergistic effects of inhaled air pollutants. She became Associate Professor of Experimental Lung Medicine at Karolinska Institutet in 2013, where she has led a research group for the past 15 years focused on molecular subtyping of chronic lung diseases, including asthma, COPD and long COVID. She is the founder and CEO of a biotech company based on innovation in protein detection. She also serves as scientific advisor to both a German and a Swedish company in the lung disease field. Wheelock was previously an independent Board member of PExA from 2021 to 2024.

Business Model

The company’s business model is based on generating income from initial sales as well as from repeat sales.

Read More ››

History

The research that resulted in PExA began in 2004 and was conducted by Anna-Carin Olin, Professor in the Department of Occupational and Environmental Medicine...

Read More ››

Business Concept and Vision

PExA’s business concept is to give lung researchers a new, unique and non-invasive method for the simple and reliable collection of potential...

Read More ››